.
The US Food and Drug Administration on Tuesday banned more than 30 generic drugs produced by Ranbaxy Laboratories Limited made at two of its factories at Dewas and Paonta Sahib. Justifying its decision, FDA said the company failed to fix numerous problems with its manufacturing operations, record keeping and procedural issues. However, Ranbaxy expressed its "disappointment" over FDA's action.